The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age
PurposeCancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. Nevertheless, we observe a failure of COVID-19 vaccines in this vulnerable population. We hypothesize that senescent peripheral T-cells alter COVID-19 vaccine-induced immunity.MethodsWe performed a monoc...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160664/full |
| _version_ | 1797813639868055552 |
|---|---|
| author | E. Orillard E. Orillard L. Spehner L. Spehner L. Mansi L. Mansi A. Bouard A. Falcoz A. Falcoz Q. Lepiller Q. Lepiller E. Renaude JR. Pallandre JR. Pallandre A. Vienot A. Vienot M. Kroemer M. Kroemer M. Kroemer C. Borg C. Borg C. Borg |
| author_facet | E. Orillard E. Orillard L. Spehner L. Spehner L. Mansi L. Mansi A. Bouard A. Falcoz A. Falcoz Q. Lepiller Q. Lepiller E. Renaude JR. Pallandre JR. Pallandre A. Vienot A. Vienot M. Kroemer M. Kroemer M. Kroemer C. Borg C. Borg C. Borg |
| author_sort | E. Orillard |
| collection | DOAJ |
| description | PurposeCancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. Nevertheless, we observe a failure of COVID-19 vaccines in this vulnerable population. We hypothesize that senescent peripheral T-cells alter COVID-19 vaccine-induced immunity.MethodsWe performed a monocentric prospective study and enrolled cancer patients and healthy donors before the COVID-19 vaccination. The primary objective was to assess the association of peripheral senescent T-cells (CD28-CD57+KLRG1+) with COVID-19 vaccine-induced immunity.ResultsEighty cancer patients have been included, with serological and specific T-cell responses evaluated before and at 3 months post-vaccination. Age ≥ 70 years was the principal clinical factor negatively influencing the serological (p=0.035) and specific SARS-CoV-2 T-cell responses (p=0.047). The presence of senescent T-cells was correlated to lower serological (p=0.049) and specific T-cell responses (p=0.009). Our results sustained the definition of a specific cut-off for senescence immune phenotype (SIP) (≥ 5% of CD4 and ≥ 39.5% of CD8 T-cells), which was correlated to a lower serological response induced by COVID-19 vaccination for CD4 and CD8 SIPhigh (p=0.039 and p=0.049 respectively). While CD4 SIP level had no impact on COVID-19 vaccine efficacy in elderly patients, our results unraveled a possible predictive role for CD4 SIPhigh T-cell levels in younger cancer patients.ConclusionsElderly cancer patients have a poor serological response to vaccination; specific strategies are needed in this population. Also, the presence of a CD4 SIPhigh affects the serological response in younger patients and seems to be a potential biomarker of no vaccinal response. |
| first_indexed | 2024-03-13T07:55:45Z |
| format | Article |
| id | doaj.art-0bc99df4bee547d4a5f1a4d48c6d81f2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T07:55:45Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0bc99df4bee547d4a5f1a4d48c6d81f22023-06-02T05:07:28ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-06-011410.3389/fimmu.2023.11606641160664The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of ageE. Orillard0E. Orillard1L. Spehner2L. Spehner3L. Mansi4L. Mansi5A. Bouard6A. Falcoz7A. Falcoz8Q. Lepiller9Q. Lepiller10E. Renaude11JR. Pallandre12JR. Pallandre13A. Vienot14A. Vienot15M. Kroemer16M. Kroemer17M. Kroemer18C. Borg19C. Borg20C. Borg21Department of Oncology, University Hospital of Besançon, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceDepartment of Oncology, University Hospital of Besançon, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceDepartment of Oncology, University Hospital of Besançon, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceITAC Platform, University of Bourgogne Franche-Comté, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceMethodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, FranceDepartment of Virology, University Hospital of Besançon, Besançon, FranceResearch Unit EA3181, Université de Franche Comté, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceITAC Platform, University of Bourgogne Franche-Comté, Besançon, FranceDepartment of Oncology, University Hospital of Besançon, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceITAC Platform, University of Bourgogne Franche-Comté, Besançon, FranceDepartment of Pharmacy, University Hospital of Besançon, Besançon, FranceDepartment of Oncology, University Hospital of Besançon, Besançon, FranceBourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie cellulaire et Génique, Besançon, FranceITAC Platform, University of Bourgogne Franche-Comté, Besançon, FrancePurposeCancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. Nevertheless, we observe a failure of COVID-19 vaccines in this vulnerable population. We hypothesize that senescent peripheral T-cells alter COVID-19 vaccine-induced immunity.MethodsWe performed a monocentric prospective study and enrolled cancer patients and healthy donors before the COVID-19 vaccination. The primary objective was to assess the association of peripheral senescent T-cells (CD28-CD57+KLRG1+) with COVID-19 vaccine-induced immunity.ResultsEighty cancer patients have been included, with serological and specific T-cell responses evaluated before and at 3 months post-vaccination. Age ≥ 70 years was the principal clinical factor negatively influencing the serological (p=0.035) and specific SARS-CoV-2 T-cell responses (p=0.047). The presence of senescent T-cells was correlated to lower serological (p=0.049) and specific T-cell responses (p=0.009). Our results sustained the definition of a specific cut-off for senescence immune phenotype (SIP) (≥ 5% of CD4 and ≥ 39.5% of CD8 T-cells), which was correlated to a lower serological response induced by COVID-19 vaccination for CD4 and CD8 SIPhigh (p=0.039 and p=0.049 respectively). While CD4 SIP level had no impact on COVID-19 vaccine efficacy in elderly patients, our results unraveled a possible predictive role for CD4 SIPhigh T-cell levels in younger cancer patients.ConclusionsElderly cancer patients have a poor serological response to vaccination; specific strategies are needed in this population. Also, the presence of a CD4 SIPhigh affects the serological response in younger patients and seems to be a potential biomarker of no vaccinal response.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160664/fullCOVID-19, vaccinationpredictive biomarkercancer patientT lymphocyte (T-cell)senescence |
| spellingShingle | E. Orillard E. Orillard L. Spehner L. Spehner L. Mansi L. Mansi A. Bouard A. Falcoz A. Falcoz Q. Lepiller Q. Lepiller E. Renaude JR. Pallandre JR. Pallandre A. Vienot A. Vienot M. Kroemer M. Kroemer M. Kroemer C. Borg C. Borg C. Borg The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age Frontiers in Immunology COVID-19, vaccination predictive biomarker cancer patient T lymphocyte (T-cell) senescence |
| title | The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age |
| title_full | The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age |
| title_fullStr | The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age |
| title_full_unstemmed | The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age |
| title_short | The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age |
| title_sort | presence of senescent peripheral t cells is negatively correlated to covid 19 vaccine induced immunity in cancer patients under 70 years of age |
| topic | COVID-19, vaccination predictive biomarker cancer patient T lymphocyte (T-cell) senescence |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160664/full |
| work_keys_str_mv | AT eorillard thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT eorillard thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lspehner thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lspehner thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lmansi thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lmansi thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT abouard thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT afalcoz thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT afalcoz thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT qlepiller thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT qlepiller thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT erenaude thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT jrpallandre thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT jrpallandre thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT avienot thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT avienot thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT mkroemer thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT mkroemer thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT mkroemer thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT cborg thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT cborg thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT cborg thepresenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT eorillard presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT eorillard presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lspehner presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lspehner presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lmansi presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT lmansi presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT abouard presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT afalcoz presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT afalcoz presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT qlepiller presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT qlepiller presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT erenaude presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT jrpallandre presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT jrpallandre presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT avienot presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT avienot presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT mkroemer presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT mkroemer presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT mkroemer presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT cborg presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT cborg presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage AT cborg presenceofsenescentperipheraltcellsisnegativelycorrelatedtocovid19vaccineinducedimmunityincancerpatientsunder70yearsofage |